AOM Infusion Recapitalized by Revelstoke Capital Partners
Deal News | Apr 15, 2025 | Revelstoke Capital Partners LL
Revelstoke Capital Partners, a private equity firm specializing in healthcare investments, has successfully completed a recapitalization of AOM Infusion. AOM, a company known for its specialty infusion services focusing on chronic therapy management, will benefit from Revelstoke's growth-oriented approach. The recapitalization aims to support AOM’s future expansion and operational capabilities in the healthcare sector. This investment marks a significant strategic move for Revelstoke as it strengthens its presence in the specialty healthcare market.
Sectors
- Healthcare
- Private Equity
Geography
- United States – The article is based on activities within the United States, where Revelstoke Capital Partners and AOM Infusion are located.
Industry
- Healthcare – The focus of both AOM Infusion and Revelstoke Capital Partners on healthcare-related services, specifically in infusion therapy, makes this a primarily healthcare-dominated investment article.
- Private Equity – Revelstoke Capital Partners is a private equity firm making a strategic investment in AOM Infusion, thus highlighting the role of private equity in healthcare advancements.
Financials
- Not disclosed – The specific financial terms of the recapitalization between Revelstoke Capital Partners and AOM Infusion were not disclosed.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Revelstoke Capital Partners | Investor | Company | A private equity firm with a focus on healthcare investments. |
| AOM Infusion | Target Company | Company | A specialty infusion provider focused on chronic therapy management. |